Genome analysis

SIGH: identifying significant intratumor genomic heterogeneity in next-generation sequencing data

Guoqiang Yu¹, Roger R. Wang^{2,†}, Sean S. Wang^{3,†}, Yue Wang¹

¹Department of Electrical and Computer Engineering, Virginia Polytechnic Institute and State University, Arlington, VA 22203, USA; ²Department of Electrical Engineering and Computer Science, University of Michigan, Ann Arbor, MI 48109, USA; ³Department of Electrical and Computer Engineering, University of Maryland, College Park, MD 20742, USA

ABSTRACT

Summary: Intratumor heterogeneity is both a major confounding factor in studying individual clones and an information source in characterizing tumor system. Intratumor heterogeneity cannot be resolved readily by global sequencing. Systematic efforts to characterize intratumor genomic heterogeneity must effectively distinguish significant genuine clonal sequences from probabilistic fake derivatives. We developed a software tool (SIGH) for identifying significant intratumor genomic heterogeneity directly from mixed sequencing reads that can improve genomic analyses in many oncological contexts. This open source software offers several attractive features: (1) it is supported by a well-grounded statistical framework that exploits probabilistic characteristics of sequencing errors; (2) it identifies genuine clonal sequences from raw sequence reads using significance tests; (3) its unbiased strategy allows detecting rare clone(s) despite that clone's relative abundance; and (4) it estimates constituent proportions in each sample. SIGH also provides the users with the ability to utilize parallel computing on ubiquitous multi-core machines.

Availability: SIGH is available as a Java-C++ package, including a user's manual, at http://www.cbil.ece.vt.edu/software.htm.

1 INTRODUCTION

Intratumor heterogeneity has been found in many cancers as evidenced by deep sequencing selectively applied to different parts of the same tumor (Bedard, et al., 2013). The complexity of heterogeneity has clinical implications. A more heterogeneous tumor is more likely to fail therapy due to increased drug-resistant variants, and characteristics of dominant clones will not necessarily predict the behaviors of driver clones (Kreso, et al., 2013; Marusyk, et al., 2012; Shibata, 2012). Intratumor heterogeneity is often manifested by multiple clones with distinct sequences that cannot be resolved readily by global sequencing and can confound studies of individual clones (Larson and Fridley, 2013).

An experimental solution to mitigate intratumor heterogeneity is to isolate pure cell populations (including immune T-cells) before sequencing. While the methods are expensive, time consuming, potentially biased and inapplicable to existing sequence data, a computational alternative was recently proposed that uses the single-nucleotide variants derived from next-generation sequencing data (Larson and Fridley, 2013). Due to inevitable sequencing errors, systematic efforts to characterize intratumor genomic heterogeneity (including immune micro-environment) must effectively distinguish significant genuine clonal sequences from probabilistic fake derivatives (Bedard, et al., 2013; Gerstung, et al., 2012) (**Fig. 1**).

We describe a statistical sequence modeling approach for detecting significant intratumor genomic heterogeneity (SIGH) directly from mixed sequencing reads rather than variant signatures. The Java-C++ SIGH software tool was developed to identify the number and sequences of genuine subclones justified by model-based significance tests. SIGH works by exploiting the statistical differences in both the sequencing error rates at different nucleobases and the read counts of fake sequences in relation to genuine clones of variable abundance. We conduct a simulation study to demonstrate the performance of SIGH under a variety of conditions on realistic synthetic data derived from immune T-cell sequences.

2 DESCRIPTION

2.1 Methods and software

Consider a tumor sample that exhibits intratumor heterogeneity (including normal cell contamination). Assume the sample contains *M* observed distinct clonal sequences that represent *M* candidate subclones. Let β_{ij} be the probability that the sequence of the *j*th candidate subclone is misclassified into the *i*th candidate subclone due to sequencing errors; n_i be the observed number of reads in the *i*th candidate subclone; and n_{ij} be the hidden number of misclassified reads in the *i*th candidate subclone that originate from the *j*th candidate subclone. When $\beta_{ij} \le 1$ and $n_{ij} \le n_{j}$, it can be shown that $N_{ij} \sim$ Poisson $(n_j\beta_{ij})$. Since $n_i = \sum_{j\neq i} n_{ij}$, under the null hypothesis (a fake subclone), it can be shown that N_i follows a Poisson distribution,

$$p(N_i = k) = \frac{\lambda_i^k e^{-\lambda_i}}{k!}, \text{ with } \lambda_i \approx \sum_{j \neq i} n_j \beta_{ij}, \tag{1}$$

i.e., the null distribution model solely due to the sequencing error.

The availability of paired tumor-normal sequences makes it possible to determine which base is misread and hence the error probability (Gerstung, et al., 2012). Let *S* be the true nucleobase; *R* be the observed nucleobase; and *S* or *R* takes one of the four nucleobases (A,C,G,T). At a single base, the (misread) error probability can be estimated by $Pr(R=r|S=s) = N_r/N_s$, where N_r is the read counts with the observed nucleobase *r* and N_s is the read counts with the true nucleobase *s*. Thus, the probability of the *j*th candidate subclone is misclassified into the *i*th candidate subclone due to sequencing error is

$$\beta_{ij} = \prod_{l} \Pr\left(R = B_i(l) \middle| S = B_j(l)\right), \tag{2}$$

⁺ These authors contributed equally to this work.

where $B_i(l)$ is the nucleobase at the *l*th location in the sequence of the *i*th candidate subclone, *L* is the sequence length, and ' $\beta_{ij} = 0$ ' if the *i*th and *j*th candidate subclones have different sequence lengths.

Given the observed read counts n_i of the *i*th candidate subclone, the p-value under the null hypothesis (the *i*th candidate subclone is fake) is

$$p_i = \sum_{k=n_i}^{\infty} \frac{\lambda_i^k e^{-\lambda_i}}{k!}.$$
(3)

Accordingly, at the significance threshold T_{a} , the *i*th candidate subclone is considered genuine if $p_i \leq T_a$; otherwise, it is fake. SIGH determines T_a by controlling the false discovery rate via: (1) sort the p-values in an increasing order denoted by $p_{(1)}, \dots, p_{(M)}$; (2) find the largest *m* such that $p_{(m)} \leq m\alpha/M$; (3) set $T_a = p_{(m)}$ for the significance level α . The reliability of the detected genuine subclones is assured by the quantitative significance measure.



Figure 1. Illustration of genuine-fake mixed sequence clusters with variable sizes: raw sequence reads suggest five tumor subclones, while actually, there are only two genuine tumor subclones.

The analytic functions in SIGH is implemented in C++, supported by a graphic user interface (GUI) written in Java, taking full advantages of both programming languages. SIGH adopts the Java Native Interface (JNI) programming framework that enables Java code to interface with the core SIGH code/libraries written in C++. SIGH allows users to easily import data, assign parameter values, save exportable analysis results, and exploit parallel computing capabilities utilizing ubiquitous multi-core machines.

2.2 Simulation studies

To demonstrate the performance of SIGH under various conditions, we conducted simulation studies based on real sequencing data from immune Tcells (PINKERTON database). Our simulations adopt settings similar to (Larson and Fridley, 2013), with L=100 and average sequencing depth at 100×. We first simulated sequence read data for normal samples by randomly replacing the nucleobase *s* by *r* at each locus of the baseline sequence, according to an error probability table (**Table 1**). We generated 10 replications of such 'training data' and examined the SIGH estimates of the error probabilities. Since error probability is generally much smaller than that of random polymorphisms, only the loci with error rates smaller than 0.1 were used in the estimation.

Table 1. Parameter settings and results for heterogeneous tumor simulations at $100\times$. The numbers of observed and genuine clonal sequence clusters identified by SIGH are reported (**illustrative**).

Probability (10 ⁻⁴ except diagonal)					Case	Proportions	SIGH
	А	С	G	Т	#	$(\lambda_1, \lambda_2, \lambda_3)$	(M, M_0, p)
А	0.99	0.29	8.70	0.48	1	(0.98, 0.01, 0.01)	(10, 3, 0.05)
С	0.27	0.99	0.38	9.62	2	(0.70, 0.10, 0.20)	(15, 3, 0.05)
G	4.82	0.19	0.99	0.45	3	(0.02, 0.05, 0.93)	(14, 3, 0.05)
Т	0.62	7.48	0.32	0.99	4	(0.11, 0.88, 0.01)	(12, 3, 0.05)

We ran similar simulations for heterogeneous tumor data with $M_0 = 3$ genuine subclones of distinct sequences for various clonal proportions (λ_1 , λ_2 , λ_3) to determine how well SIGH could detect intratumor heterogeneity and identify genuine subclone sequences. We tested SIGH on 10 replications of each unique set of conditions.

For each application of SIGH, mean per-sample execution time was ~2 minutes on a computer equipped with an Intel® CoreTM 2 Duo E6600, AMD AthlonTM 64 X2 5000+ (24 cores and 12 GB of RAM).

Detailed descriptions on method, software, and results on synthetic data are included in the supplementary information.

3 RESULTS AND DISCUSSION

For the normal sample simulations, SIGH accurately learned read error probabilities in all replications. For the heterogeneous tumor samples with variable subclonal proportions, SIGH correctly identified three genuine subclones and hence revealed intratumor heterogeneity, in all replications, reported in **Table 1**. As a significance testing approach, measures of confidence are directly derived from the null distribution of n_i in the form of p values (**Table 1**). SIGH also accurately estimated the genuine subclonal proportions (Supplementary Data).

Our simulation studies demonstrate the feasibility of identifying intratumor genomic heterogeneity in the presence of inevitable sequencing error. By statistically modeling read count null distributions for each of the observed sequence clusters, SIGH can potentially identify rare genuine subclone(s) directly from genuine-fake mixed raw or mutant sequence reads, despite abundance disparity between subclones. When applied to longitudinal studies, SIGH may also provide additional information about tumor evolution or clonal repopulation dynamics (Kreso, et al., 2013).

We foresee a variety of extensions to the concepts and strategies in SIGH. For example, with further development, SIGH methodology can be applicable to analyzing the raw sequences of circulating tumor cells (CTCs) in peripheral blood. The potential ability to detect sequence reads associated with CTCs is clinically significant, since CTCs constitute seeds for subsequent growth of metastasized tumors in vital distant organs, triggering a mechanism that is responsible for the vast majority of cancer-related deaths. Such applications highlight the unique role of SIGH for detecting rare genuine subclones in many oncological contexts (Bedard, et al., 2013).

Funding: National Institutes of Health, under Contract HHS-N2612200800001E, Grants HL111362 and CA160036, in part.

Conflict of Interest: none declared.

REFERENCES

Bedard, P.L., *et al.* (2013) Tumour heterogeneity in the clinic, *Nature*, **501**, 355-364. Gerstung, M., *et al.* (2012) Reliable detection of subclonal single-nucleotide variants in tumour cell populations, *Nature communications*, **3**, 811.

Kreso, A., et al. (2013) Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer, *Science*, **339**, 543-548.

Larson, N.B. and Fridley, B.L. (2013) PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data, *Bioinformatics*, **29**, 1888-1889.

Marusyk, A., Almendro, V. and Polyak, K. (2012) Intra-tumour heterogeneity: a looking glass for cancer?, *Nat Rev Cancer*, **12**, 323-334.

Shibata, D. (2012) Cancer. Heterogeneity and tumor history, Science, 336, 304-305.